Patents Assigned to AstraZeneca UK Limited
-
Patent number: 11972844Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: GrantFiled: May 18, 2021Date of Patent: April 30, 2024Assignee: ASTRAZENECA UK LIMITEDInventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Publication number: 20230372527Abstract: A pharmaceutical product for administration of an anti-HER2 antibody-drug conjugate in combination with a PARP1 selective inhibitor is provided. The anti-HER2 antibody drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the PARP1 selective inhibitor are administered in combination to a subject: Formula (I).Type: ApplicationFiled: October 8, 2021Publication date: November 23, 2023Applicants: AstraZeneca UK Limited, Daiichi Sankyo Company, LimitedInventors: Jerome Thomas METTETAL, II, Azadeh Cheraghchi Bashi ASTANEH, Elisabetta LEO, Yann WALLEZ
-
Patent number: 11817195Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 5, 2022Date of Patent: November 14, 2023Assignee: ASTRAZENECA UK LIMITEDInventors: Robert Peter Prybolsky, Judy Firor
-
Patent number: 11817188Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a biguanide anti-hyperglycemic pharmaceutical composition to a subject qualified for over-the-counter access to the biguanide anti-hyperglycemic pharmaceutical composition. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes N,N-dimethylimidodicarbonimidic diamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes metformin hydrochloride.Type: GrantFiled: October 5, 2022Date of Patent: November 14, 2023Assignee: ASTRAZENECA UK LIMITEDInventors: Robert Peter Prybolsky, Judy Firor
-
Patent number: 11793788Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a dipeptidyl peptidase-4 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the dipeptidyl peptidase-4 inhibitor pharmaceutical composition. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes saxagliptin, sitagliptin, linagliptin, alogliptin, or a pharmaceutically acceptable salt thereof. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 13, 2019Date of Patent: October 24, 2023Assignee: ASTRAZENECA UK LIMITEDInventors: Robert Peter Prybolsky, Judy Firor
-
Patent number: 11798661Abstract: A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 11, 2022Date of Patent: October 24, 2023Assignee: ASTRAZENECA UK LIMITEDInventors: Richard L. Skelly, Judy Firor
-
Publication number: 20230330243Abstract: A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond.Type: ApplicationFiled: June 23, 2021Publication date: October 19, 2023Applicants: Daiichi Sankyo Company, Limited, AstraZeneca UK LimitedInventors: Jerome Thomas METTETAL, II, Stephen Thomas DURANT, Azadeh Cheraghchi Bashi ASTANEH, Alan Yin Kai LAU, Yann WALLEZ
-
Patent number: 11756656Abstract: A method is provided for treating or preventing symptoms of asthma in a subject in need thereof by administering a corticosteroid pharmaceutical composition to a subject qualified for over-the-counter access to the corticosteroid pharmaceutical composition. In some embodiments, the corticosteroid pharmaceutical composition includes a class B corticosteroid, a glucocorticosteroid, budesonide, ciclesonide, fluticasone furoate, mometasone furoate, fluticasone propionate, or beclomethasone dipropionate.Type: GrantFiled: June 13, 2019Date of Patent: September 12, 2023Assignee: ASTRAZENECA UK LIMITEDInventors: Robert Peter Prybolsky, Judy Firor
-
Publication number: 20230256110Abstract: A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATM inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the ATM inhibitor are administered in combination to a subject: Formula (I).Type: ApplicationFiled: June 23, 2021Publication date: August 17, 2023Applicants: AstraZeneca UK Limited, DAIICHI SANKYO COMPANY, LIMITEDInventors: Jerome Thomas METTETAL, II, Stephen Thomas DURANT, Azadeh Cheraghchi Bashi ASTANEH, Alan Yin Kai LAU, Yann WALLEZ
-
Publication number: 20230233540Abstract: A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with a CDK9 inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond.Type: ApplicationFiled: June 23, 2021Publication date: July 27, 2023Applicants: AstraZeneca UK Limited, DAIICHI SANKYO COMPANY, LIMITEDInventors: Jerome Thomas METTETAL, II, Justin Robert CIDADO, Scott BOIKO
-
Publication number: 20230201331Abstract: The invention relates to A composition comprising a viral vector, wherein the viral vector is an adenovirus based vector, the viral vector comprising nucleic acid having a polynucleotide sequence encoding a polypeptide, said polypeptide having an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, characterised in that said polypeptide comprises the following substitutions relative to SEQ ID NO: 1: L18F, D80A, G215D, L242 ?, A243 ?, L244 ?, K417N, E484K, N501Y, D614G; and A701V. The invention also related to uses and methods.Type: ApplicationFiled: June 7, 2022Publication date: June 29, 2023Applicant: Astrazeneca UK LimitedInventors: Helen BRIGHT, David TABOR
-
Patent number: 11651865Abstract: A method is provided for lowering blood pressure in a subject in need thereof by administering an angiotensin II receptor blocker pharmaceutical composition to a subject qualified for over-the-counter access to the angiotensin II receptor blocker pharmaceutical composition. In some embodiments, the angiotensin II receptor blocker pharmaceutical composition includes azilsartan medoxomil, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan. In some embodiments, the angiotensin II receptor blocker pharmaceutical composition comprises an active ingredient that is (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2?-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 29, 2021Date of Patent: May 16, 2023Assignee: ASTRAZENECA UK LIMITEDInventors: Richard L. Skelly, Judy Firor, James Blasetto
-
Patent number: 11501857Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a biguanide anti-hyperglycemic pharmaceutical composition to a subject qualified for over-the-counter access to the biguanide anti-hyperglycemic pharmaceutical composition. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes N,N-dimethylimidodicarbonimidic diamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes metformin hydrochloride.Type: GrantFiled: June 13, 2019Date of Patent: November 15, 2022Assignee: ASTRAZENECA UK LIMITEDInventors: Robert Peter Prybolsky, Judy Firor
-
Patent number: 11495339Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 13, 2019Date of Patent: November 8, 2022Assignee: ASTRAZENECA UK LIMITEDInventors: Robert Peter Prybolsky, Judy Firor
-
Patent number: 11430555Abstract: A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.Type: GrantFiled: December 23, 2020Date of Patent: August 30, 2022Assignee: ASTRAZENECA UK LIMITEDInventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Patent number: 11417416Abstract: A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 13, 2019Date of Patent: August 16, 2022Assignee: ASTRAZENECA UK LIMITEDInventors: Richard L. Skelly, Judy Firor
-
Patent number: 11348670Abstract: A method is provided for treating erectile dysfunction in a subject in need thereof by administering a cGMP-specific phosphodiesterase 5 (PDE5) inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the PDE5 inhibitor pharmaceutical composition. In some embodiments, the PDE5 inhibitor pharmaceutical composition includes tadalafil or vardenafil.Type: GrantFiled: June 13, 2019Date of Patent: May 31, 2022Assignee: ASTRAZENECA UK LIMITEDInventors: Richard L. Skelly, Judy Firor
-
Publication number: 20210355196Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.Type: ApplicationFiled: May 17, 2021Publication date: November 18, 2021Applicant: AstraZeneca UK LimitedInventors: Mark ESSER, James STEINHARDT, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, Saravanan RAJAN
-
Patent number: 11081240Abstract: A method is provided for lowering blood pressure in a subject in need thereof by administering an angiotensin II receptor blocker pharmaceutical composition to a subject qualified for over-the-counter access to the angiotensin II receptor blocker pharmaceutical composition. In some embodiments, the angiotensin II receptor blocker pharmaceutical composition includes azilsartan medoxomil, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan. In some embodiments, the angiotensin II receptor blocker pharmaceutical composition comprises an active ingredient that is (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2?-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 13, 2019Date of Patent: August 3, 2021Assignee: ASTRAZENECA UK LIMITEDInventors: Richard L. Skelly, Judy Firor, James Blasetto
-
Publication number: 20190365751Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: December 18, 2018Publication date: December 5, 2019Applicant: AstraZeneca UK LimitedInventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz